Stelara's Triumph At NICE May Highlight Improved Focus on Drug Value
This article was originally published in The Pink Sheet Daily
Executive Summary
A patient access scheme from Janssen has seen Stelara through the NICE process for active psoriatic arthritis, but this doesn't mean the cost watchdog is back to focusing cost.
You may also be interested in...
Stelara And Firmagon Suffer Setbacks In Draft NICE Appraisals
Janssen has until Jan. 17 to argue the cost-effectiveness of Stelara in the additional indication, psoriatic arthritis, while Ferring faces a restricted indication recommendation for Firmagon.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.